Haffkine Biopharma to produce 22.8 cr doses of Covaxin per annum
With the aim of vaccinating the entire eligible population at the earliest, domestic vaccine production is being steadily ramped up in the country with the help from the Centre
Photo Courtesy: IANS
Engagement: 0
The Centre on Wednesday took steps to accelerate domestic vaccine production. Mumbai-based Haffkine Biopharma will produce 22.8 crore doses per annum of Covaxin under technology transfer arrangement with Bharat Biotech.
With the aim of vaccinating the entire eligible population at the earliest, domestic vaccine production is being steadily ramped up in the country with the help from the Centre.